PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors

Authors:

Abstract
Significance: Targeting epigenetic dependencies caused by mutations in chromatin-modifying enzymes represents a novel therapeutic approach in cancer. Notably, cancers harboring mutations in the SNF5 subunit of the SWI/SNF chromatin remodeling complex have been shown to be susceptible to small-molecule inhibitors of the EZH2 histone methyltransferase that are currently in clinical development. We demonstrate that EZH2 inhibition can be effective in SMARCA4 mutant cancers that concurrently transcriptionally silence the paralog helicase SMARCA2. SMARCA2 is directly suppressed by EZH2, and SMARCA2 expression levels predict EZH2 inhibitor activity in other SWI/SNF mutant contexts, including ARID1A mutant tumors. These data provide insight into the utility of EZH2 inhibitors in SWI/SNF mutant tumors and have important implications regarding predictive diagnostics.

This publication has 37 references indexed in Scilit: